Abstract

Pleomorphic adenomas represent 80% of the salivary gland’s benign tumors. They are most often found in the parotid gland or in the submandibular gland. Pleomorphic adenomas of the nasal cavity are rare, with less than fifty cases reported to date. There are no treatment or follow up guidelines. The purpose of this article is to review the cases already described in the literature and to share our clinical experience. We describe the case of a 38-year-old woman with a history of a slow growing intranasal tumor with recurrent epistaxis, obstruction, and aesthetic deformation. The pre-operative assessment suggested a benign tumor, but the biopsies were inconclusive. The decision was taken to perform an open rhinoplasty to have an en bloc resection with margins control. The diagnosis of pleomorphic adenoma was established on the excised tumor. There were no post-operative complications. The early follow-up showed no signs of recurrence. We decided to closely follow the patient with frequent clinical examinations and yearly enhanced-MRIs for at least five years due to the recurrence and malignant transformation risks.

Highlights

  • Salivary gland tumors are rare, they represent around 3 % of all neoplasms

  • Pleomorphic adenomas represent 80% of the salivary gland’s benign tumors

  • Pleomorphic adenomas (PAs) represent 80% of benign tumors and are mostly found in the parotid gland or in the submandibular gland

Read more

Summary

Introduction

Salivary gland tumors are rare, they represent around 3 % of all neoplasms. They are mainly located within the major salivary glands. Pleomorphic adenomas (PAs) represent 80% of benign tumors and are mostly found in the parotid gland or in the submandibular gland. 8 to 10 % of PAs grow in the minor salivary glands [1, 2]. PAs are benign tumors which are at a risk of transforming into malignant tumors, mostly into carcinoma ex pleomorphic adenoma [3]. In the literature [1, 4], this risk is estimated between 0% and 6% and increases further when the diagnosis of the tumor is delayed. If there is a malignant change, the prognosis gets worse, with a 5 years survival rate ranging between 30 to 50% [2]

Objectives
Findings
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.